Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients

Acta Neurologica Scandinavica

Volumn 97, Issue 5, 1998, Pages 295-299

  Pierelli, F ^a   Adipietro, A ^a   Soldati, G ^b   Fattapposta, F ^a   Pozzessere, G ^b   Scoppetta, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Clozapine; Dyskinesias; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; CLOZAPINE; LEVODOPA; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; SCORING SYSTEM; SEDATION; TREATMENT OUTCOME;

EID: 0031947236     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1998.tb05955.x     Document Type: Article

References (29)

1. LHERMITTE F, AGID Y, SIGNORET JL, STUDLER JM. Les dyskinesies de debut et fin dose "provoquées" par la L-dopa. Rev Neurol 1977: 133: 297-308.
2. 2 antagonist FCE 23884 on Parkinson's Disease. Mov Dis 1996: 11: 257-60.
3. INZELBERG R, NISIPEANU P, RABEY MJ, KORCZYN AD. Long-term tolerability and efficacy of Cabergoline, a new long-actina dopamine agonist, in Parkinson's Disease. Mov Dis 1995: 10: 604-7.
4. MOURADIAN MM, HEUSER IJ, BARONTI F, FABBRINI G, JUNCOS JL, CHASE TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989: 25: 523-6.
5. CEDERBUM JM. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's Disease. Neurol Clin North Am 1990: 8: 31-49.
6. PFEIFFER RF, KANG J, GRABER B HOFMAN R, WILSON J. Clozapine for psychosis in Parkinson's Disease. Mov Disord 1990: 5: 239-42.
7. FACTOR SA, BROWN D. Clozapine prevents recurrence of psychosis in Parkinson's Disease. Mov Dis 1992: 7: 125-131.
8. , dopamine receptor-mediated behaviors. Eur J Pharmacol 1989: 159: 141-7.
9. 2 receptor-mediated function: behavioral indices. Eur J Pharmacol 1990: 186: 79-86.
10. 4 receptor with affinity for the antipsychotic clozapine. Nature 1991: 350: 610-14.
11. WOLTERS ECH, HURWITZ TA, MAK E et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990: 40: 832-4.
12. LIDSKY TI, YABLONSKY-ALTER E, ZUCK L, BANERJEE SP. Anti-glutamatergic effects of clozapine. Neurosci Lett 1993: 163: 155-8.
13. FACTOR SA, BROWN D, MOLHO ES, PODSKALNY GD. Clozapine: a 2-year open trial in Parkinson's Disease patients with psychosis. Neurology 1994: 44: 544-6.
14. BENNETT JP, LANDOW ER, SCHUH LA. Suppression of dyskinesias in Parkinson's disease II: increasing daily clozapine doses suppresses dyskinesias and improve parkinsonism symptoms. Neurology 1993: 43: 1551-4.
15. BENNETT JP, LANDOW ER, DIETRICH S, SCHUH LA. Suppression of dyskinesias in advanced Parkinson's disease: moderate dayli clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994: 9: 409-14.
16. DURIF F, VIDAILHET M, ASSAL F, ROCHE C, BONNET AM, AGID Y. Low dose clozapine improve dyskinesias in Parkinson's disease. Neurology 1997: 48: 658-62.
17. BARBEAU A. Parkinson's disease: clinical features and etiopathology. In: VINKEN PJ, BRUYN GW, KLAWANS HL, eds. Handbook of clinical neurology, vol. 5(49): extrapiramidal disorders. Amsterdam: Elsevier Science, 1986: 87-152.
18. HUGHES AJ, DANIEL SE, KILFORD L, LEES AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992: 55: 181-4.
19. DERICK TW. Measurement in neurological rehabilitation: Oxford Medical Publications, 1995.
20. KLAWANS HL, GOETZ C, NAUSIEDA PA, WEINER WJ. Levodopa-induced dopamine receptor hypersensitivity. Ann Neurol 1977: 2: 125-9.
21. KISH SJ, SHANNAK HK, HORNYKIEWICZ O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease - pathophysiologic and clinical implications. N Engl J Med 1988: 318: 876-80.
22. ALEXANDER GE, CRUTCHER MD. Functional architecture of basal ganglia circuits and neural substrates of parallel processing. Trends Neurosci 1990: 13: 266-71.
23. 2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 1990: 40: 927-33.
24. 2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 1992: 31: 551-4.
25. 1 dopamine receptors in the basal ganglia of the cat and primate: delineation of striosomal compartments and pallidal and nigral subdivisions. Neuroscience 1988: 26: 101-19.
26. CROSSMAN AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990: 5: 100-8.
27. CROSSMAN AR, MITCHELL IJ, SAMBROOK MA, JACKSON A. Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and hypothesis for the neural mechanisms of chorea. Brain 1988: 111: 1211-33.
28. 2 receptors. Nature 1980: 286: 157-9.
29. KUHAR MJ. Neuroanatomical substrates of anxiety: a brief survey. Trends Neurosci 1986: 9: 311-13.